Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-Line of Treatment of Patients With Glioblastoma Multiforme.

Next Previous
Search
Trial Profile

A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-Line of Treatment of Patients With Glioblastoma Multiforme.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jun 2012 Planned end date changed from 1 Aug 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 02 May 2011 Planned end date changed from 1 Dec 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 11 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top